Related Topics:
Facility ID: 45215GRNDS856RE
Facility Name and Address: NITTO DENKO AVECIA INC. 8560 READING RD CINCINNATI, OH 45215 Parent Company: NITTO DENKO AVECIA INC Industry: Pharmaceutical Preparation Manufacturing (325412) Chemical: Toluene Reports: View TRI Facility profile report for this facility View TRI Form R submissions by this facility |
|
*You can navigate within the map with your mouse. |
Production Related Waste Management for Selected Chemical
lchemid=0000108883
Chart Options1: |
Waste Management Comparison -
Display facility comparison report for this industry and chemical
Display facility comparison report for this parent company
Pollution Prevention Activities for Selected Chemical
Reporting Year | Section 8.10: Newly Implemented Source Reduction Activity | Section 8.10: Methods to Identify Activity | Section 8.11: Optional Pollution Prevention Information* |
---|---|---|---|
2019 |
Source Reduction:: W29: Other changes in inventory control
|
Methods to Identify SR Opportunities: T03: Materials balance audits
|
W29: Reduced inventory volumes for efficiency and lowering materials kept onsite. Source Reduction - Periodic inventory assessments to assure volumes on hold are reduced to minimum needed. |
2018 |
Source Reduction:: W29: Other changes in inventory control
|
Methods to Identify SR Opportunities: T03: Materials balance audits
|
W29: Reduced inventory volumes for efficiency and lowering materials kept onsite. Source Reduction - Periodic inventory assessments to assure volumes on hold are reduced to minimum needed. |
2017 |
Source Reduction:: W29: Other changes in inventory control
|
Methods to Identify SR Opportunities: T03: Materials balance audits
|
W29: Reduced inventory volumes for efficiency and lowering materials kept on-site. Source Reduction - Periodic inventory assessments to assure volumes on hold are reduced to minimum needed. |
2016 |
Barriers: B7-Barriers to P2 B7 - No known substitutes or alternative technologies.
|
Barriers to P2: B7 - No known substitutes or alternative technologies. - Currently the oligonucleotide synthesis process and relevant R&D does not have an alternate chemical product. Source Reduction: Source Reduction - By removing large lab suite and updating processes chemical reduction is expected. |